Yongdong Niu1,2,3, Meishu Xu1, Betty L Slagle4, Haihua Huang5, Song Li1, Grace L Guo6, Ganggang Shi3, Wenxin Qin2, Wen Xie1. 1. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA. 2. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China. 4. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX. 5. Department of Pathology, Second Affiliated Hospital of Shantou University Medical College, Guangdong, China. 6. Department of Pharmacology and Toxicology, School of Pharmacy, Rutgers University, Piscataway, NJ.
Abstract
Chronic hepatitis B virus infection is a major risk factor for hepatocellular carcinoma (HCC). Hepatitis B virus X protein (HBx) is a hepatitis B virus protein that has multiple cellular functions, but its role in HCC pathogenesis has been controversial. Farnesoid X receptor (FXR) is a nuclear receptor with activities in anti-inflammation and inhibition of hepatocarcinogenesis. However, whether or how FXR can impact hepatitis B virus/HBx-induced hepatocarcinogenesis remains unclear. In this study, we showed that HBx can interact with FXR and function as a coactivator of FXR. Expression of HBx in vivo enhanced FXR-responsive gene regulation. HBx also increased the transcriptional activity of FXR in a luciferase reporter gene assay. The HBx-FXR interaction was confirmed by coimmunoprecipitation and glutathione S-transferase pull-down assays, and the FXR activation function 1 domain was mapped to bind to the third α helix in the C terminus of HBx. We also found that the C-terminally truncated variants of HBx, which were found in clinical HCC, were not effective at transactivating FXR. Interestingly, recruitment of the full-length HBx, but not the C-terminally truncated HBx, enhanced the binding of FXR to its response element. In vivo, FXR ablation markedly sensitized mice to HBx-induced hepatocarcinogenesis. CONCLUSIONS: We propose that transactivation of FXR by full-length HBx may represent a protective mechanism to inhibit HCC and that this inhibition may be compromised upon the appearance of C-terminally truncated HBx or when the expression and/or activity of FXR is decreased. (Hepatology 2017;65:893-906).
Chronic hepatitis B virus infection is a major risk factor for hepatocellular carcinoma (HCC). Hepatitis B virus X protein (HBx) is a hepatitis B virus protein that has multiple cellular functions, but its role in HCC pathogenesis has been controversial. Farnesoid X receptor (FXR) is a nuclear receptor with activities in anti-inflammation and inhibition of hepatocarcinogenesis. However, whether or how FXR can impact hepatitis B virus/HBx-induced hepatocarcinogenesis remains unclear. In this study, we showed that HBx can interact with FXR and function as a coactivator of FXR. Expression of HBx in vivo enhanced FXR-responsive gene regulation. HBx also increased the transcriptional activity of FXR in a luciferase reporter gene assay. The HBx-FXR interaction was confirmed by coimmunoprecipitation and glutathione S-transferase pull-down assays, and the FXR activation function 1 domain was mapped to bind to the third α helix in the C terminus of HBx. We also found that the C-terminally truncated variants of HBx, which were found in clinical HCC, were not effective at transactivating FXR. Interestingly, recruitment of the full-length HBx, but not the C-terminally truncated HBx, enhanced the binding of FXR to its response element. In vivo, FXR ablation markedly sensitized mice to HBx-induced hepatocarcinogenesis. CONCLUSIONS: We propose that transactivation of FXR by full-length HBx may represent a protective mechanism to inhibit HCC and that this inhibition may be compromised upon the appearance of C-terminally truncated HBx or when the expression and/or activity of FXR is decreased. (Hepatology 2017;65:893-906).
Authors: H Tu; C Bonura; C Giannini; H Mouly; P Soussan; M Kew; P Paterlini-Bréchot; C Bréchot; D Kremsdorf Journal: Cancer Res Date: 2001-11-01 Impact factor: 12.701
Authors: Guodong Li; Bo Kong; Yan Zhu; Le Zhan; Jessica A Williams; Ossama Tawfik; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo Journal: Toxicol Appl Pharmacol Date: 2013-06-26 Impact factor: 4.219
Authors: Ying Hu; Samuel W French; Thinh Chau; Hui-Xin Liu; Lili Sheng; Fang Wei; Jesse Stondell; Juan C Garcia; Yanlei Du; Christopher L Bowlus; Yu-Jui Yvonne Wan Journal: FASEB J Date: 2018-09-25 Impact factor: 5.191